Hong Kong Auto Stock News

COSCO SHIPPING International (Hong Kong) (SEHK:517) shares were in focus after the company reported the passing of independent non executive director Mr. Kwong Che Keung, Gordon, who also chaired its audit committee. See our latest analysis for COSCO SHIPPING International (Hong Kong). The recent board change comes at a time when COSCO SHIPPING International (Hong Kong) shares trade at HK$5.44, with a 30 day share price return that is down 9.33% and a 90 day share price return that is down...

Kuaishou Technology (SEHK:1024) began repurchasing its shares on July 3, 2026 under a shareholder-mandated program allowing buybacks of up to 432,690,765 shares, or 10% of its issued capital, funded from legally available resources in line with Cayman Islands regulations. The company expects these repurchases, alongside its recent quarterly revenue growth and HK$2.88 billion net profit, to lift net asset value per share and/or earnings per share, underscoring management’s focus on capital...

Many Duality Biotherapeutics, Inc. ( HKG:9606 ) insiders ditched their stock over the past year, which may be of...

China Tobacco International (HK) (SEHK:6055) is back in focus after chairman and non executive director Mr. Shao Yan retired, leaving key board and committee roles temporarily vacant and prompting interim governance arrangements. See our latest analysis for China Tobacco International (HK). China Tobacco International (HK)'s share price has fallen 6.85% over the past month and 42.85% over the past 90 days, yet its 3 year total shareholder return of 91.10% means longer term holders have still...

Innovent Biologics (SEHK:1801) has drawn fresh attention after securing exclusive commercialization rights for Eli Lilly’s breast cancer drug Verzenios in mainland China. This adds a reimbursed oncology product to its existing portfolio. See our latest analysis for Innovent Biologics. The Verzenios agreement lands at a time when Innovent Biologics’ share price has a 30 day share price return of 22.96% and a year to date share price return of 13.83%. Its 3 year total shareholder return of...

Dividend details and key dates for Huishang Bank stock Huishang Bank (SEHK:3698) has approved a final ordinary cash dividend of RMB 2.5 per 10 shares, or HK$2.87488 per 10 shares, for the 2025 financial year. Shareholders approved the payout on 30 June 2026, with the ex-dividend date set for 6 July, the record date on 13 July, and payment scheduled for 21 August 2026. See our latest analysis for Huishang Bank. Huishang Bank's share price is HK$4.54, with a 1 day share price return of 1.11%...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Shougang...

Looking at BeijingWest Industries International Limited's ( HKG:2339 ) insider transactions over the last year, we can...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Board moves on capital and governance draw focus to Shanghai Conant Optical Shanghai Conant Optical (SEHK:2276) has put a proposed reduction of its registered capital and amendments to its Articles of Association on the agenda, bringing corporate structure and governance questions to the foreground for investors. See our latest analysis for Shanghai Conant Optical. For Shanghai Conant Optical, the latest HK$31.78 share price sits against a short-term backdrop of weaker momentum, with the...

Pico Far East Holdings (SEHK:752) has reported its H1 2026 results with context that matters for investors, coming off H2 2025 revenue of HK$3.7 billion, basic EPS of HK$0.178, and net income of HK$223.7 million. The company has seen revenue move from HK$3.4 billion with EPS of HK$0.134 in H2 2024 to HK$3.5 billion and EPS of HK$0.171 in H1 2025, before reaching HK$3.7 billion and EPS of HK$0.179 in H2 2025, against a backdrop of trailing 12 month earnings growth of 14.1%. With net profit...

WuXi Biologics (Cayman) (SEHK:2269) is back in focus after its MFG8 facility in Hebei cleared a seven day U.S. FDA Pre License Inspection, supporting commercial production of a potential autoimmune therapy. See our latest analysis for WuXi Biologics (Cayman). At a share price of HK$37.96, WuXi Biologics (Cayman) has seen a 26.79% 30 day share price return and a 16.66% year to date share price return. Its 1 year total shareholder return of 42.44% contrasts with weaker multi year total...

Seazen Group (SEHK:1030) has released a new sales and trading update, reporting unaudited contracted sales of about RMB 6.357b for the first half of 2026 and highlighting ongoing uncertainty around these preliminary figures. See our latest analysis for Seazen Group. The new contracted sales update lands after a tough stretch for Seazen Group’s stock, with the 30 day share price return down 20.47% and the year to date share price return down 34.30%. The 1 year total shareholder return has...

Lenovo Group (SEHK:992), as FIFA's Official Technology Partner, is set to showcase AI powered tools at the FIFA World Cup 2026™. The company is providing applications such as Referee View and analytics platforms for coaches and fans throughout the tournament. These deployments put Lenovo’s AI solutions in front of a global audience during one of the world’s highest profile sporting events. For investors tracking Lenovo Group, this World Cup role highlights how the company is positioning...

J&T Global Express (SEHK:1519) just released its Q2 2026 operating results, highlighting parcel volume milestones and rapid growth in non China deliveries. The update gives investors fresh data on how the global network is scaling. See our latest analysis for J&T Global Express. The latest Q2 operating update landed as J&T Global Express trades at HK$9.08, with a 30-day share price return of 3.30% but a 90-day share price decline of 18.12%. The 1-year total shareholder return is 1.45%,...

Shanghai Henlius Biotech (SEHK:2696) is back in focus after Chinese regulators cleared phase 1 trials for its HLX37 combination therapies, while a separate study for bispecific ADC HLX48 has already started dosing patients. See our latest analysis for Shanghai Henlius Biotech. The latest HLX37 and HLX48 updates come after a mixed stretch for Shanghai Henlius Biotech, with the share price up 9.77% over 30 days but down 24.54% over 90 days, while the 1 year and 3 year total shareholder returns...

Greentown China Holdings (SEHK:3900) has released unaudited sales figures for June and the first half of 2026, giving investors fresh detail on contracted volumes, pricing and project management activity. See our latest analysis for Greentown China Holdings. Following these June sales figures, Greentown China Holdings’ share price has softened, with a 30 day share price return of 18.68% and a 1 year total shareholder return decline of 33.04%, suggesting recent momentum has been weak despite...

CK Asset Holdings (SEHK:1113) has tendered a 2,137 square foot, four bedroom unit in phase 2 of its 21 Borrett Road project for over HK$157 million, highlighting fresh activity in its Hong Kong luxury portfolio. See our latest analysis for CK Asset Holdings. CK Asset Holdings' latest luxury sale comes as the stock trades at HK$45.46, with a 7 day share price return of 2.66% and a year to date share price return of 12.8%. The 1 year total shareholder return of 35.19% suggests momentum has been...

China Tobacco International (HK) Company Limited announced that, effective July 2, 2026, chairman and non-executive director Mr. Shao Yan retired, leaving vacancies across key board and committee roles and temporarily putting the company out of full compliance with Hong Kong listing rules. Beyond the leadership change itself, the immediate gaps in the nomination and remuneration committees highlight how even planned retirements can ripple through corporate governance structures. We’ll now...

While Dongyue Group Limited ( HKG:189 ) might not have the largest market cap around , it saw a significant share price...

While C.banner International Holdings Limited ( HKG:1028 ) shareholders have enjoyed a good week with stock up 12...

Zhongshen Jianye Holding Limited ( HKG:2503 ) shareholders (or potential shareholders) will be happy to see that the...

InnoCare Pharma (SEHK:9969) is back in focus after new clinical data showed its BTK inhibitor orelabrutinib was well tolerated and clinically effective in a large Phase IIb study for systemic lupus erythematosus. See our latest analysis for InnoCare Pharma. Alongside the positive lupus data, InnoCare Pharma has also started dosing patients in China with its CDH17 targeted ADC ICP-B208. The stock’s recent momentum reflects this, with a 1 month share price return of 34.55% but a 1 year total...